OwlTail

Cover image of Ola Landgren

Ola Landgren

10 Podcast Episodes

Latest 9 Oct 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Multiple Myeloma | Ola Landgren, MD, PhD

Research To Practice | Oncology Videos

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 2: Other Novel Strategies with Potential to Improve Outcomes in MM — Dr Landgren. CME information and select publications

28mins

20 Feb 2021

Episode artwork

Debate: Treatment of Smoldering Myeloma: What Treatment is Ideal? - C. Ola Landgren, MD, PhD and Joseph R. Mikhael, MD, MEd, FRCPC

HMP CME (Audio)

Multiple Myeloma: Treatment Challenges and Updates

29mins

20 Dec 2019

Similar People

Episode artwork

Debate: Treatment of Smoldering Myeloma: What Treatment is Ideal? - C. Ola Landgren, MD, PhD and Joseph R. Mikhael, MD, MEd, FRCPC

HMP CME (Video)

Multiple Myeloma: Treatment Challenges and Updates

29mins

20 Dec 2019

Episode artwork

C. Ola Landgren, MD, PhD: DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes

HMP CME (Video)

Webcast: Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment?

16mins

31 Oct 2018

Most Popular

Episode artwork

C. Ola Landgren, MD, PhD: DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes

HMP CME (Audio)

Webcast: Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment?

16mins

31 Oct 2018

Episode artwork

Myeloma Crowd Radio: Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Ctr

Myeloma Crowd Radio

For the last 50 years, myeloma studies have relied on myeloma progression measurements like complete response (CR) or progression free survival (PFS) to tell whether new treatmets are working (or not). Myeloma patients are now living longer because of new treatment advances, which is a huge blessing. But it is also a challenge for research. If the average patient is living 8-10 years, how can studies be performed and show results in the 2-3 year range so that the new drugs can be approved quickly? Minimal residual disease testing can detect very low levels of disease and being MRD-negative is linked to patients living longer. Researchers would like to use MRD testing as a study measurement. Learn about the different types of MRD tests, how to have one done and why researchers want to use this test as an end-point in studies. Dr. Ola Landgren of the Memorial Sloan Kettering Cancer Center is a pioneer in the MRD space and joins us for this important show.Thanks to our episode sponsor, Takeda Oncology

1hr 10mins

12 Jan 2017

Episode artwork

Community Questions 15 | Interview with Ola Landgren, MD, PhD

Hematologic Oncology Update

A special audio supplement to a CME symposia series held during the 2015 ASH Annual Meeting. Interview with Ola Landgren, MD, PhD conducted by Neil Love, MD. Produced by Research To Practice.

39mins

10 May 2016

Episode artwork

Myeloma Crowd Radio: Dr. Ola Landgren, MD, PhD, Memorial Sloan Kettering

Myeloma Crowd Radio

New developments for multiple myeloma are happening at an ever increasing pace. Dr. Ola Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and heavily involved in the direction of myeloma research, both nationally and internationally. In this show he will give a wrap up of the recent Rome International Myeloma Working Group meeting as well as an ASH preview (for the upcoming December conference). He will also share up and coming clinical trials at Memorial Sloan Kettering Cancer Center to incorporate these new treatments into clinical practice. Learn what new drugs will be available and how they can be used in the myeloma clinic.

1hr 20mins

20 Nov 2015

Episode artwork

CACU1 2015 | Interview with Ola Landgren, MD, PhD

Cancer Conference Update

Interview with Ola Landgren, MD, PhD conducted by Neil Love, MD. Produced by Research To Practice.

39mins

22 Apr 2015

Episode artwork

mPatient Myeloma Radio: Dr. C. Ola Landgren, NCI

Myeloma Crowd Radio

This week on mPatient Myeloma Radio, listen to Dr. Landgren as we discuss his research in new therapies for myeloma in its precursor states (MGUS and smoldering), molecular profiling of myeloma and why it is important in predicting progression, and his related research with myeloma and the immune system.

1hr 3mins

2 Aug 2013